Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis: Results From an NTM Info & Research Patient Survey and the Bronchiectasis and NTM Research Registry

Emily Henkle, Timothy Aksamit, Alan F. Barker, Jeffrey R. Curtis, Charles L. Daley, M. Leigh Anne Daniels, Angela DiMango, Edward Eden, Kevin Fennelly, David E. Griffith, Margaret Johnson, Michael R. Knowles, Amy Leitman, Philip Leitman, Elisha Malanga, Mark L. Metersky, Peadar G. Noone, Anne E. O'Donnell, Kenneth N. Olivier, Delia PrietoMatthias Salathe, Byron Thomashow, Gregory Tino, Gerard Turino, Susan Wisclenny, Kevin L. Winthrop

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background Non-cystic fibrosis bronchiectasis (“bronchiectasis”) is a chronic inflammatory lung disease often associated with nontuberculous mycobacteria (NTM) infection. Very little data exist to guide bronchiectasis management decisions. We sought to describe patterns of inhaled corticosteroid (ICS) and antibiotic therapy in the United States. Methods We invited 2,000 patients through NTM Info & Research (NTMir) to complete an anonymous electronic survey. We separately queried baseline clinical and laboratory data from the US Bronchiectasis and NTM Research Registry (BRR). Results Among 511 NTMir survey responders with bronchiectasis, whose median age was 67 years, 85 (17%) reported asthma and 99 (19%) reported COPD. History of ICS use was reported by 282 (55%), 171 (61%) of whom were treated 1 year or longer, and 150 (53%) were currently taking ICSs. Fewer reported ever taking azithromycin for non-NTM bronchiectasis (203 responders [40%]) or inhaled tobramycin (78 responders [15%]). The median age of 1,912 BRR patients was 69 years; 528 (28%) had asthma and 360 (19%) had COPD. Among 740 patients (42%) without NTM, 314 were taking ICSs at baseline. Among patients without NTM who were taking ICSs, only 178 (57%) had a concurrent diagnosis of COPD or asthma that could explain ICS use. Fewer were taking suppressive macrolides (96 patients [13%]), and of the 70 patients (10%) taking inhaled suppressive antibiotics, 48 (68%) had chronic Pseudomonas aeruginosa infection. Conclusions ICS use was common in two national samples of patients with bronchiectasis, with relatively few patients taking suppressive antibiotic therapies. Further research is needed to clarify the safety and effectiveness of these therapies in patients with bronchiectasis.

Original languageEnglish (US)
Pages (from-to)1120-1127
Number of pages8
JournalChest
Volume152
Issue number6
DOIs
StatePublished - Dec 1 2017

Fingerprint

Nontuberculous Mycobacteria
Bronchiectasis
Registries
Fibrosis
Drug Therapy
Research
Adrenal Cortex Hormones
Chronic Obstructive Pulmonary Disease
Asthma
Anti-Bacterial Agents
Nontuberculous Mycobacterium Infections
Surveys and Questionnaires
Pseudomonas Infections
Azithromycin
Tobramycin
Macrolides
Mycobacterium
Pseudomonas aeruginosa
Lung Diseases
Therapeutics

Keywords

  • bronchiectasis
  • inhaled antibiotics
  • inhaled corticosteroids
  • macrolides

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis : Results From an NTM Info & Research Patient Survey and the Bronchiectasis and NTM Research Registry. / Henkle, Emily; Aksamit, Timothy; Barker, Alan F.; Curtis, Jeffrey R.; Daley, Charles L.; Anne Daniels, M. Leigh; DiMango, Angela; Eden, Edward; Fennelly, Kevin; Griffith, David E.; Johnson, Margaret; Knowles, Michael R.; Leitman, Amy; Leitman, Philip; Malanga, Elisha; Metersky, Mark L.; Noone, Peadar G.; O'Donnell, Anne E.; Olivier, Kenneth N.; Prieto, Delia; Salathe, Matthias; Thomashow, Byron; Tino, Gregory; Turino, Gerard; Wisclenny, Susan; Winthrop, Kevin L.

In: Chest, Vol. 152, No. 6, 01.12.2017, p. 1120-1127.

Research output: Contribution to journalArticle

Henkle, E, Aksamit, T, Barker, AF, Curtis, JR, Daley, CL, Anne Daniels, ML, DiMango, A, Eden, E, Fennelly, K, Griffith, DE, Johnson, M, Knowles, MR, Leitman, A, Leitman, P, Malanga, E, Metersky, ML, Noone, PG, O'Donnell, AE, Olivier, KN, Prieto, D, Salathe, M, Thomashow, B, Tino, G, Turino, G, Wisclenny, S & Winthrop, KL 2017, 'Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis: Results From an NTM Info & Research Patient Survey and the Bronchiectasis and NTM Research Registry', Chest, vol. 152, no. 6, pp. 1120-1127. https://doi.org/10.1016/j.chest.2017.04.167
Henkle, Emily ; Aksamit, Timothy ; Barker, Alan F. ; Curtis, Jeffrey R. ; Daley, Charles L. ; Anne Daniels, M. Leigh ; DiMango, Angela ; Eden, Edward ; Fennelly, Kevin ; Griffith, David E. ; Johnson, Margaret ; Knowles, Michael R. ; Leitman, Amy ; Leitman, Philip ; Malanga, Elisha ; Metersky, Mark L. ; Noone, Peadar G. ; O'Donnell, Anne E. ; Olivier, Kenneth N. ; Prieto, Delia ; Salathe, Matthias ; Thomashow, Byron ; Tino, Gregory ; Turino, Gerard ; Wisclenny, Susan ; Winthrop, Kevin L. / Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis : Results From an NTM Info & Research Patient Survey and the Bronchiectasis and NTM Research Registry. In: Chest. 2017 ; Vol. 152, No. 6. pp. 1120-1127.
@article{827f0d96376b4f0d8266df6debeca14a,
title = "Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis: Results From an NTM Info & Research Patient Survey and the Bronchiectasis and NTM Research Registry",
abstract = "Background Non-cystic fibrosis bronchiectasis (“bronchiectasis”) is a chronic inflammatory lung disease often associated with nontuberculous mycobacteria (NTM) infection. Very little data exist to guide bronchiectasis management decisions. We sought to describe patterns of inhaled corticosteroid (ICS) and antibiotic therapy in the United States. Methods We invited 2,000 patients through NTM Info & Research (NTMir) to complete an anonymous electronic survey. We separately queried baseline clinical and laboratory data from the US Bronchiectasis and NTM Research Registry (BRR). Results Among 511 NTMir survey responders with bronchiectasis, whose median age was 67 years, 85 (17{\%}) reported asthma and 99 (19{\%}) reported COPD. History of ICS use was reported by 282 (55{\%}), 171 (61{\%}) of whom were treated 1 year or longer, and 150 (53{\%}) were currently taking ICSs. Fewer reported ever taking azithromycin for non-NTM bronchiectasis (203 responders [40{\%}]) or inhaled tobramycin (78 responders [15{\%}]). The median age of 1,912 BRR patients was 69 years; 528 (28{\%}) had asthma and 360 (19{\%}) had COPD. Among 740 patients (42{\%}) without NTM, 314 were taking ICSs at baseline. Among patients without NTM who were taking ICSs, only 178 (57{\%}) had a concurrent diagnosis of COPD or asthma that could explain ICS use. Fewer were taking suppressive macrolides (96 patients [13{\%}]), and of the 70 patients (10{\%}) taking inhaled suppressive antibiotics, 48 (68{\%}) had chronic Pseudomonas aeruginosa infection. Conclusions ICS use was common in two national samples of patients with bronchiectasis, with relatively few patients taking suppressive antibiotic therapies. Further research is needed to clarify the safety and effectiveness of these therapies in patients with bronchiectasis.",
keywords = "bronchiectasis, inhaled antibiotics, inhaled corticosteroids, macrolides",
author = "Emily Henkle and Timothy Aksamit and Barker, {Alan F.} and Curtis, {Jeffrey R.} and Daley, {Charles L.} and {Anne Daniels}, {M. Leigh} and Angela DiMango and Edward Eden and Kevin Fennelly and Griffith, {David E.} and Margaret Johnson and Knowles, {Michael R.} and Amy Leitman and Philip Leitman and Elisha Malanga and Metersky, {Mark L.} and Noone, {Peadar G.} and O'Donnell, {Anne E.} and Olivier, {Kenneth N.} and Delia Prieto and Matthias Salathe and Byron Thomashow and Gregory Tino and Gerard Turino and Susan Wisclenny and Winthrop, {Kevin L.}",
year = "2017",
month = "12",
day = "1",
doi = "10.1016/j.chest.2017.04.167",
language = "English (US)",
volume = "152",
pages = "1120--1127",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "6",

}

TY - JOUR

T1 - Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis

T2 - Results From an NTM Info & Research Patient Survey and the Bronchiectasis and NTM Research Registry

AU - Henkle, Emily

AU - Aksamit, Timothy

AU - Barker, Alan F.

AU - Curtis, Jeffrey R.

AU - Daley, Charles L.

AU - Anne Daniels, M. Leigh

AU - DiMango, Angela

AU - Eden, Edward

AU - Fennelly, Kevin

AU - Griffith, David E.

AU - Johnson, Margaret

AU - Knowles, Michael R.

AU - Leitman, Amy

AU - Leitman, Philip

AU - Malanga, Elisha

AU - Metersky, Mark L.

AU - Noone, Peadar G.

AU - O'Donnell, Anne E.

AU - Olivier, Kenneth N.

AU - Prieto, Delia

AU - Salathe, Matthias

AU - Thomashow, Byron

AU - Tino, Gregory

AU - Turino, Gerard

AU - Wisclenny, Susan

AU - Winthrop, Kevin L.

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Background Non-cystic fibrosis bronchiectasis (“bronchiectasis”) is a chronic inflammatory lung disease often associated with nontuberculous mycobacteria (NTM) infection. Very little data exist to guide bronchiectasis management decisions. We sought to describe patterns of inhaled corticosteroid (ICS) and antibiotic therapy in the United States. Methods We invited 2,000 patients through NTM Info & Research (NTMir) to complete an anonymous electronic survey. We separately queried baseline clinical and laboratory data from the US Bronchiectasis and NTM Research Registry (BRR). Results Among 511 NTMir survey responders with bronchiectasis, whose median age was 67 years, 85 (17%) reported asthma and 99 (19%) reported COPD. History of ICS use was reported by 282 (55%), 171 (61%) of whom were treated 1 year or longer, and 150 (53%) were currently taking ICSs. Fewer reported ever taking azithromycin for non-NTM bronchiectasis (203 responders [40%]) or inhaled tobramycin (78 responders [15%]). The median age of 1,912 BRR patients was 69 years; 528 (28%) had asthma and 360 (19%) had COPD. Among 740 patients (42%) without NTM, 314 were taking ICSs at baseline. Among patients without NTM who were taking ICSs, only 178 (57%) had a concurrent diagnosis of COPD or asthma that could explain ICS use. Fewer were taking suppressive macrolides (96 patients [13%]), and of the 70 patients (10%) taking inhaled suppressive antibiotics, 48 (68%) had chronic Pseudomonas aeruginosa infection. Conclusions ICS use was common in two national samples of patients with bronchiectasis, with relatively few patients taking suppressive antibiotic therapies. Further research is needed to clarify the safety and effectiveness of these therapies in patients with bronchiectasis.

AB - Background Non-cystic fibrosis bronchiectasis (“bronchiectasis”) is a chronic inflammatory lung disease often associated with nontuberculous mycobacteria (NTM) infection. Very little data exist to guide bronchiectasis management decisions. We sought to describe patterns of inhaled corticosteroid (ICS) and antibiotic therapy in the United States. Methods We invited 2,000 patients through NTM Info & Research (NTMir) to complete an anonymous electronic survey. We separately queried baseline clinical and laboratory data from the US Bronchiectasis and NTM Research Registry (BRR). Results Among 511 NTMir survey responders with bronchiectasis, whose median age was 67 years, 85 (17%) reported asthma and 99 (19%) reported COPD. History of ICS use was reported by 282 (55%), 171 (61%) of whom were treated 1 year or longer, and 150 (53%) were currently taking ICSs. Fewer reported ever taking azithromycin for non-NTM bronchiectasis (203 responders [40%]) or inhaled tobramycin (78 responders [15%]). The median age of 1,912 BRR patients was 69 years; 528 (28%) had asthma and 360 (19%) had COPD. Among 740 patients (42%) without NTM, 314 were taking ICSs at baseline. Among patients without NTM who were taking ICSs, only 178 (57%) had a concurrent diagnosis of COPD or asthma that could explain ICS use. Fewer were taking suppressive macrolides (96 patients [13%]), and of the 70 patients (10%) taking inhaled suppressive antibiotics, 48 (68%) had chronic Pseudomonas aeruginosa infection. Conclusions ICS use was common in two national samples of patients with bronchiectasis, with relatively few patients taking suppressive antibiotic therapies. Further research is needed to clarify the safety and effectiveness of these therapies in patients with bronchiectasis.

KW - bronchiectasis

KW - inhaled antibiotics

KW - inhaled corticosteroids

KW - macrolides

UR - http://www.scopus.com/inward/record.url?scp=85038222653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038222653&partnerID=8YFLogxK

U2 - 10.1016/j.chest.2017.04.167

DO - 10.1016/j.chest.2017.04.167

M3 - Article

C2 - 28479113

AN - SCOPUS:85038222653

VL - 152

SP - 1120

EP - 1127

JO - Chest

JF - Chest

SN - 0012-3692

IS - 6

ER -